Article Text

other Versions

The Science of Pterygium
  1. Jay C Bradley (docjayb{at},
  2. William Yang (william.yang{at},
  3. Rachael H Bradley (rhbradley{at},
  4. Ted W Reid (ted.reid{at},
  5. Ivan R Schwab (irschwab{at}
  1. Texas Tech Health Sciences Center, United States
  2. Texas Tech University Health Sciences Center, United States
  3. Texas Tech University Health Sciences Center, United States
  4. Texas Tech University Health Sciences Center, United States
  5. University of California, Davis, United States


    Pterygium is an ocular surface disease of humans attributed to chronic ultraviolet-B (UV-B) exposure. Clinically, the condition involves invasive centripetal growth with associated inflammation and neovascularization. Prior clinical studies focused primarily on the clinical characteristics and surgical management of pterygia and, due to this fact, the pathogenesis of pterygia remains incompletely understood. However, considerable progress in this area has been achieved, providing additional insight into this complex disease. This recent evidence implicates anti-apoptotic mechanisms, immunological mechanisms, cytokines, growth factors, extracellular matrix modulators, genetic factors, viral infections, and other possible causative factors. Limited investigation regarding differences in pathogenesis of primary and recurrent pterygia has been performed. We summarize many of these recent discoveries concerning the pathogenesis of pterygia and describe reported differences between primary and recurrent pterygia.

    Statistics from

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.